stella
beta
Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study — Stella
Recruiting
Back to Ovarian Cancer Metastatic trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(2 sites)
China
Jiangsu Cancer Hospital, Nanjing, Jiangsu
Jiangsu Cancer Hospital, Nanjing, Jiangsu
View full record on ClinicalTrials.gov